| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.08 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.078 | 0.08 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | -0.056 | 0.08 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.064 | 0.08 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.078 | 0.08 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.054 | 0.09 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.068 | 0.1 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |